Mr. Yoash Zohar, CEO of Casterra states: "This additional order reflects the confidence in Casterra's capabilities and in our castor seed varieties, developed utilizing Evogene's GeneRator AI tech-engine and Casterra's advanced breeding methods, and marks a significant step in our expansion into Africa. We expect that our previously announced seed production, now totaling 900 tons, will more than support this order, which is expected to be completed by Q4 2024, as well as earlier purchase orders received la ...

Operator Such statements are based on current expectations, estimates, projections and assumptions describe opinions about future events, involve certain risks and uncertainties, which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, perf ...

Title: Preliminary results from a First-in-Human (FIH), open-label Phase 1 study with BMC128, a rationally designed live bacterial consortium, in combination with nivolumab. Session Type: Poster Session Abstract Number: 8631 Date and Time: June 3, 2024, 1:30 PM – 4:30 PM (CDT) Key observations from the study include: With these encouraging early results, it is important to note that the study remains ongoing. Further data will become available and analyzed through the next few months to gain a deeper unders ...

Conference call and webcast: today, May 23, 2024, 9:00 am ET Financial and Business Highlights: REHOVOT, Israel, May 23, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products, today announced its financial results for the first quarter period ended March 31, 2024. Mr. Ofer Haviv, Evogene's President and CEO, stated: "Evogene's mission is to direct and accelerate the development of life-sci ...

Company Overview - Casterra Ag Ltd. is an integrated solutions company focused on the cultivation of castor for bio-based industrial applications, including biofuels and biopolymers [3] - The company has developed a broad collection of over 300 castor lines from 40 different geographic and climatic regions, enhancing its genetic assets [3] - Casterra employs advanced breeding methods and utilizes Evogene's GeneRator AI tech engine to enable efficient and sustainable industrial-scale production of castor beans [3] Strategic Partnerships - Casterra is expanding partnerships with existing and new seed producers to strengthen production capabilities and meet the dynamic needs of customers and markets globally [2] - This proactive commitment aims to mitigate potential production risks and establish a reliable seed production infrastructure [2] Technological Innovation - Casterra utilizes Evogene's GeneRator AI tech engine, which is part of a suite of technologies aimed at revolutionizing life-science-based product development [4] - The tech engine leverages Big Data and Artificial Intelligence to enhance the discovery and development of genetic elements for agricultural applications [4][5] Market Position - Casterra is positioning itself as a leading company in providing comprehensive solutions for the commercial cultivation of castor plants specifically for the biofuel industry [2]

Preliminary data from Biomica's Phase 1 study of BMC128 will be showcased at the conference REHOVOT, Israel, April 16, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that it will present preliminary data from its Phase 1 study of BMC128, in combination with immune checkpoint inhibitor (ICI) immunotherapy, in refractory patients with either non-small ...

The pre-clinical work was led by Prof. Yehuda Ringel, Biomica's Co-Founder and CSO, in collaboration with the lab of Prof. Kara Gross Margolis, at the NYU Grossman School of Medicine. In the studies, Biomica tested two candidate therapeutic consortia of live bacterial strains, BMC426 and BMC427. Treatment with these drug candidates effectively reduced visceral pain, a major symptom of IBS. Presentation Details: Session Type: Research ForumSession Title: Gut Instincts: Exploring the Interplay of the Microbio ...

Execution Version Exhibit 10.1 EVOGENE LTD. $7.3 Million of Ordinary Shares (par value NIS 0.02 per share) Sales Agreement March 28, 2024 Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Evogene Ltd., a company organized under the laws of the State of Israel (the "Company"), confirms its agreement (this "Agreement") with Lake Street Capital Markets, LLC (the "Agent"), as follows: 1. Issuance and Sale of Shares. The Company agrees that, fr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F | ☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | --- | --- | | | OR | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended December 31, 2023 | | | OR | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | OR | | ☐ | SHELL COMPANY REPORT PURSUANT TO SECTION ...

"We believe that regenerative agriculture is an integral part of addressing climate change and creating positive outcomes for both our farm partners and our planet", said Carlos Paz, President and CEO at Ceres Global Ag Corp. "By collaborating with Lavie Bio, we are well-positioned to foster more efficient growing practices and continue to offer tailored solutions to strategic customers". Lavie Bio is focused on transformation of the crop input sector through the development of biologicals as alternatives f ...